Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-cash Items (2017 - 2025)

Aclaris Therapeutics has reported Non-cash Items over the past 9 years, most recently at $8.6 million for Q4 2025.

  • Quarterly results put Non-cash Items at $8.6 million for Q4 2025, up 189.66% from a year ago — trailing twelve months through Dec 2025 was $8.6 million (up 189.66% YoY), and the annual figure for FY2025 was $8.6 million, up 189.66%.
  • Non-cash Items for Q4 2025 was $8.6 million at Aclaris Therapeutics, up from $2.2 million in the prior quarter.
  • Over the last five years, Non-cash Items for ACRS hit a ceiling of $40.3 million in Q1 2023 and a floor of $13000.0 in Q3 2024.
  • Median Non-cash Items over the past 5 years was $15.1 million (2022), compared with a mean of $15.6 million.
  • Biggest five-year swings in Non-cash Items: skyrocketed 151004.76% in 2021 and later crashed 99.91% in 2023.
  • Aclaris Therapeutics' Non-cash Items stood at $13.7 million in 2021, then increased by 11.51% to $15.3 million in 2022, then crashed by 99.91% to $14000.0 in 2023, then skyrocketed by 21100.0% to $3.0 million in 2024, then skyrocketed by 189.66% to $8.6 million in 2025.
  • The last three reported values for Non-cash Items were $8.6 million (Q4 2025), $2.2 million (Q3 2025), and $14.0 million (Q2 2025) per Business Quant data.